Protease-activated receptors in cardiovascular health and diseases

American Heart Journal

Volumn 157, Issue 2, 2009, Pages 253-262

  Shah, Rahman ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; AU 4; BLOOD CLOTTING FACTOR 10A; BMS 200261; CATHEPSIN G; CLOPIDOGREL; E 5555; ELASTASE; FIBRINOGEN RECEPTOR ANTAGONIST; HIMBACINE; MYELOBLASTIN; PLASMIN; PROTEINASE ACTIVATED RECEPTOR; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 1 ANTAGONIST; PROTEINASE ACTIVATED RECEPTOR 2; PROTEINASE ACTIVATED RECEPTOR 2 ANTAGONIST; PROTEINASE ACTIVATED RECEPTOR 3; PROTEINASE ACTIVATED RECEPTOR 4; RWJ 56110; SCH 205831; SCH 530348; THROMBIN; THROMBIN RECEPTOR; THROMBIN RECEPTOR ANTAGONIST; TRYPSIN; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; UNCLASSIFIED DRUG; UNINDEXED DRUG; WJ 58259;

ATHEROSCLEROSIS; BLOOD CLOTTING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; HEART INFARCTION; HUMAN; INFLAMMATION; MORTALITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RECEPTOR DENSITY; REVIEW; RISK REDUCTION; STROKE; THROMBOSIS;

CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; HUMANS; PLATELET AGGREGATION INHIBITORS; RECEPTORS, PROTEINASE-ACTIVATED;

EID: 58649088469     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2008.09.025     Document Type: Review

References (43)

1. Lopez A.D., and Murray C. The global burden of disease1990-2020. Nat Med 4 (1998) 1241-1243
2. Lusis A.J. Atherosclerosis. Nature 407 (2000) 233-241
3. Ruggeri Z.M. Platelets in atherothrombosis. Nat Med 8 (2002) 1227-1234
4. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324 (2002) 71-86
5. Kong D.F., Hasselblad V., Harrington R.A., et al. Meta-analysis of survival with platelet glycoprotein IIb/IIIa antagonists for percutaneous coronary interventions. Am J Cardiol 92 (2003) 651-655
6. Kahn M.L., Zheng Y.-W., Huang W., et al. A dual thrombin receptor system for platelet activation. Nature 394 (1998) 690-694
7. Wess J. Molecular basis of receptor/G-protein-coupling selectivity. Pharmacol Ther 80 (1998) 231-264
8. Drews J. Drug discovery: a historical perspective. Science 287 (2000) 1960-1964
9. Coughlin S.R. Thrombin signalling and protease-activated receptors. Nature 407 (2000) 258-264
10. Xu W.-f., Andersen H., Whitmore T.E., et al. Cloning and characterization of human protease-activated receptor 4. Proc Natl Acad Sci U S A 95 (1998) 6642-6646
11. Covic L., Misra M., Badar J., et al. Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation. Nat Med 8 (2002) 1161-1165
12. Covic L., Gresser A.L., and Kuliopulos A. Biphasic kinetics of activation and signaling for PAR1 and PAR4 thrombin receptors in platelets. Biochemistry 39 (2000) 5458-5467
13. Leger A.J., Jacques S.L., Badar J., et al. Blocking the protease-activated receptor 1-4 heterodimer in platelet-mediated thrombosis. Circulation 113 (2006) 1244-1254
14. Johnson K., Choi Y., DeGroot E., et al. Potential mechanisms for a proinflammatory vascular cytokine response to coagulation activation. J Immunol 160 (1998) 5130-5135
15. Vouret-Craviari V., Bourcier C., Boulter E., et al. Distinct signals via Rho GTPases and Src drive shape changes by thrombin and sphingosine-1-phosphate in endothelial cells. J Cell Sci 115 (2002) 2475-2484
16. Hirano K., and Kanaide H. Role of protease-activated receptors in the vascular system. J Atheroscler Thromb 10 (2003) 211-225
17. Robin J., Kharbanda R., McLean P., et al. Protease-activated receptor 2-mediated vasodilatation in humans in vivo: role of nitric oxide and prostanoids. Circulation 107 (2003) 954-959
18. Ku D.D., and Dai J. Expression of thrombin receptors in human atherosclerotic coronary arteries leads to an exaggerated vasoconstrictory response in vitro. J Cardiovasc Pharmaco 30 (1997) 649-657
19. Sabri A., Muske G., Zhang H., Pak E., et al. Signaling properties and functions of two distinct cardiomyocyte protease-activated receptors. Circ Res 86 (2000) 1054-1061
20. Yasutake M., Haworth R.S., King A., et al. Thrombin activates the sarcolemmal Na+-H+ exchanger: evidence for a receptor-mediated mechanism involving protein kinase C. Circ Res 79 (1996) 705-715
21. Jiang T., Kuznetsov V., Pak E., et al. Thrombin receptor actions in neonatal rat ventricular myocytes. Circ Res 78 (1996) 553-563
22. Glembotski C.C., Irons C.E., Krown K.A., et al. Myocardial alpha-thrombin receptor activation induces hypertrophy and increases atrial natriuretic factor gene expression. J Biol Chem 268 (1993) 20646-20652
23. Bretschneider E., Kaufmann R., and Braun M. Evidence for proteinase-activated receptor-2 (PAR-2) mediated mitogenesis in coronary artery smooth muscle cells. Br J Pharmacol. 126 (1999) 1735-1740
24. Dabbagh K., Laurent G.J., and McAnulty R.J. Thrombin stimulates smooth muscle cell procollagen synthesis and mRNA levels via a PAR1 mediated mechanism. Thromb Haemost 79 (1998) 405-409
25. Barry G.D., Le G.T., and Fairlie D.P. Agonists and antagonists of protease activated receptors (PARs). Curr Med Chem 13 (2006) 243-265
26. Bernatowicz M.S., Klimas C.E., Hartl K.S., et al. Development of potent thrombin receptor antagonist peptides. J Med Chem 39 (1996) 4879-4887
27. Derian C.K., Damiano B.P., Addo M.F., et al. Blockade of the thrombin receptor protease-activated receptor-1 with a small-molecule antagonist prevents thrombus formation and vascular occlusion in nonhuman primates. J Pharmacol Exp Ther 304 (2003) 855-861
28. Chackalamannil S., Xia Y., Greenlee W.J., et al. Discovery of potent orally active thrombin receptor (protease activated receptor 1) antagonists as novel antithrombotic agents. J Med Chem 48 (2005) 5884-5887
29. Serebruany V.L., Miller M., Pokov A.N., et al. Effect of statins on platelet PAR-1 thrombin receptor in patients with the metabolic syndrome (from the PAR-1 Inhibition by Statins [PARIS] study). Am J Cardiol 97 (2006) 1332-1336
30. Day J.R.S., Punjabi P.P., Randi A.M., et al. Clinical inhibition of the seven-transmembrane thrombin receptor (PAR1) by intravenous aprotinin during cardiothoracic surgery. Circulation 110 (2004) 2597-2600
31. Wu C.C., Hwang T.L., Liao C.H., et al. Selective inhibition of protease-activated receptor 4-dependent platelet activation by YD-3. Thromb Haemost 87 (2002)
32. Kelso E.B., Lockhart J.C., Hembrough T., et al. Therapeutic promise of proteinase-activated receptor-2 antagonism in joint inflammation. J Pharmacol Exp Ther 316 (2006) 1017-1024
33. Kaneider N.C., Agarwal A., Leger A.J., et al. Reversing systemic inflammatory response syndrome with chemokine receptor pepducins. Nat Med 11 (2005) 661-665
34. Kosoglou T., Reydeman L., Fales R.R., et al. Pharmacodynamics, and pharmacokinetics of novel protease-activated receptor antagonist SCH 530348. Circulation 112 Suppl (2005) 32
35. Moliterno D.J., Becker R.C., Jennings L.K., et al. Results from a multinational randomized, double-blind, placebo-controlled study of a novel thrombin receptor antagonist SCH 530348 in percutaneous coronary intervention. 56th Annual Session of the American College of Cardiology Annual Meeting, 24-27 March 2007. in New Orleans, Louisiana, USA. Abstract 2402-9. (2007)
36. Novel antiplatelet may reduce events without increasing bleeding. Available at:. http://www.medscape.com/viewarticle/554131 Last accessed March 2008
37. Schering-Plough. Schering-Plough announces initiation of two phase III clinical trials for novel selective antiplatelet therapy (TRA-SCH 530348) [press release]. April 18, 2007. Available at:. http://www.schering-plough.com/schering_plough/news/release.jsp?releaseID=987054 Last accessed March 2008
38. Trial to assess the effects of SCH 530348 in preventing heart attack and stroke in patients with atherosclerosis (TRA 2°P-TIMI 50) (Study P04737). Available at:. http://www.clinicaltrials.gov/ct/gui/show/NCT00526474?order=1 Last accessed March 2008
39. Trial to assess the effects of SCH 530348 in preventing heart attack and stroke in patients with acute coronary syndrome (TRA•CER) (Study P04736). Available at:. http://www.clinicaltrials.gov/ct/gui/show/NCT00527943?order=2 Last accessed March 2008
40. Characteristics of E5555. Available at:. www.eisai.co.jp/pdf/eir/emat/material20050830e.pdf Last accessed July 2008
41. Husted S. New developments in oral antiplatelet therapy. Eur Heart J Suppl 9 (2007) D20-D27
42. Eisai Medical Research Inc. Study of E5555 and its effects on markers of intravascular inflammation in subjects with coronary artery disease. Available at:. http://www.clinicaltrials.gov/ct/show/NCT00312052 Last accessed July 2008
43. A double-blind study of E5555 in Japanese patients with acute coronary syndrome. Available at:. http://www.clinicaltrials.gov/ct2/show/NCT00619164 Last accessed July 2008